Tracking down metabolic vulnerabilities in CDK12-mutant prostate cancer
Date
2024-08-01
Authors
Journal Title
Journal ISSN
Volume Title
Citation Stats
Attention Stats
Abstract
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Tu, Wei-Ling, Mu-En Wang and Ming Chen (2024). Tracking down metabolic vulnerabilities in CDK12-mutant prostate cancer. Clinical and Translational Discovery, 4(4). 10.1002/ctd2.345 Retrieved from https://hdl.handle.net/10161/31308.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Ming Chen
Our laboratory is interested in understanding the molecular and genetic events underlying cancer progression and metastasis. The focus of our work is a series of genetically engineered mouse models that faithfully recapitulate human disease. Using a combination of mouse genetics, omics technologies, cross-species analyses and in vitro approaches, we aim to identify cancer cell–intrinsic and –extrinsic mechanisms driving metastatic cancer progression, with a long–term goal of developing new therapeutic strategies for preventing and treating metastatic disease.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.